I have always been a bear and I am too old and tired to change my ways now. But reader J insists that I am wrong and flourishes the research note below from a key shareholder in Scancell (SCLP) which makes the bull case. As a believer in free speech I am happy to platform both sides of the debate. Enjoy
Between now and 28th July you can win a week at the Greek Hovel paying just a cleaning and pool fee – by explaining in 300-1000 words why if you had to bet everything on one share on a three year view what that share would be. To see how to enter go HERE and PLEASE KEEP SENDING IN ENTRIES. Thirty fourth up is Honest John
AIM-listed former favourite of mine Scancell (SCLP) offered up its interim results to October 2023 this morning. There is lots of promise – as ever – but what bothers me is cashburn.
AIM-listed biotech Scancell (SCLP) has announced that it has raised £1.2 million from the Open Offer attached to its recent fundraise. The good news for the company is, of course, it has another £1.2 million (before expenses) but I think this is bad news for shareholders.
AIM-listed biotech Scancell (SCLP) announced a placing after hours yesterday – at 5.03pm, no-one-is-watching o’clock. The plan was to raise £6 million at 11p per share. This morning it was announced it had raised £10.6 million – well done, Scancell. Who could have known?
AIM-listed Scancell (SCLP) released full-year numbers to April yesterday morning – on deadline day, never a good sign. Having flagged up potential going concerns, how do the numbers look?
AIM-listed biotech Scancell (SCLP) ‘fessed up this morning that its full year results to April would be further delayed, originally promised for Thursday of last week and then 24th October. Now we are told they will be released as soon as the auditor completes their final processes – in other words, no fixed date. Is there anything to worry about here?
AIM-listed Scancell (SCLP) was a company that I tipped – very unsuccessfully – in the past, on hopes of making pots of cash out of its medical technology. I sold, and needless to say, the shares then shot higher amid the Covid pandemic. But more recently, the ski-slope (downwards) reasserted. Until this morning.
As readers will know I was a big fan of AIM-listed biotech Scancell (SCLP) but lost my patience with what appeared to be an attempt to jump on the Covid bandwagon. Well blow me down, for today the shares have doubled to 28.25p at peak this morning. What’s going on (apart from me looking like a prize chump)?
There was bad news this morning from AIM-listed cancer-buster Scancell (SCLP): Cancer Research UK has pulled out of a funding deal to put Scancell’s second SCIB product through Phase I/II trials.
I have documented over many years what a rotten investment Scancell (SCLP) has been but its spoofing on its quest for a Covid vaccine is one of the biggest red flags fluttering. Today it plunged new depths of spoofery as it announced a collaboration with Cobra Biologics “for Cobra to manufacture Scancell's COVID-19 vaccine.” Great, except that…
Having previously bravely (or perhaps stupidly) held on to my bullish beliefs in AIM-listed Scancell (SCLP), I finally threw in the towel last week after what appeared to be an attempted ramp by jumping on the Covid-19 bandwagon. I said sell – and it appears it was not just me looking to get out...
One of my first ever tips for ShareProphets was AIM-listed Scancell (SCLP), way back in the 2015 New Year tipfest. It has not covered me in glory, having tipped it when it was hanging around the 23-33p mark as the shares closed last night at around 5p. I had hoped that it would turn itself around and its biotech business would find a willing buyer in the end. But today the shares are up buy a thumping 46% (last seen) on news of Development of vaccine against Covid-19. Should I be celebrating? I’m not so sure….
Pharmaceuticals isn’t a sector that I generally tend to invest in, other than possibly for the dividends paid by some of the huge multinational companies.
AIM-listed immunotherapy cancer specialist Scancell (SCLP) announced last week that the FDA had posed a few questions regarding its application to run a Phase II combination trial for its SCIB-1 skin cancer compound alongside a checkpoint inhibitor. The market saw this as bad news, and marked the shares down heavily – but I’m not so sure it is all that serious.
